Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM) - VBI Vaccines

Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

November 22, 2019 |

Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Conference: 2019 Annual Meeting of the Society for Neuro-Oncology (SNO)
Date: November 22, 2019

View More

March 13, 2023

VBI Vaccines Reports Full Year 2022 Financial Results

February 23, 2023

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

February 15, 2023

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

December 8, 2022

VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI